Pandemic rattles already vulnerable antibiotics market

A report from the biopharmaceutical industry published earlier this year found that 47% of the 65 responding companies experienced product supply chain disruptions of antibiotics.

With more countries shutting borders, trade restrictions in India and manufacturing disruptions in China, there are growing concerns that meeting rising demand could prove even more difficult.

Enea Martinelli, head pharmacist at the FMI hospital in Interlaken told swissinfo.ch that hospitals in Switzerland are getting organised and that supply isn’t a problem now. But he worries about what’s ahead in a few months’ time.